Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 4, 2013, Pages 822-828

  Villard, Elise F ^a,b   Ei Khoury, Petra ^a,b   Frisdal, Eric ^a,b   Bruckert, Eric ^a,b   Clement, Karine ^a,c   Bonnefont Rousselot, Dominique ^a,d   Bittar, Randa ^a,b   Le Goff, Wilfried ^a,b   Guerin, Maryse ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

cholesterol efflux; high density lipoprotein; macrophages; single nucleotide polymorphisms

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FEMALE; GENDER IDENTITY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MACROPHAGE; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CELL LINE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LIPASE; LIPID METABOLISM; MACROPHAGES; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; SEX FACTORS; TRIGLYCERIDES;

EID: 84875370988     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300979     Document Type: Article

References (47)

1. Brewer HB Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92:23K-29K.
2. Wang X, Paigen B. Genetics of variation in HDL cholesterol in humans and mice. Circ Res. 2005;96:27-42.
3. Chen SN, Cilingiroglu M, Todd J, Lombardi R, Willerson JT, Gotto AM Jr, Ballantyne CM, Marian AJ. Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet. 2009;10:111.
4. Peloso GM, Demissie S, Collins D, Mirel DB, Gabriel SB, Cupples LA, Robins SJ, Schaefer EJ, Brousseau ME. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDLcholesterol and coronary heart disease. J Lipid Res. 2010;51:3524-3532.
5. Wang K, Edmondson AC, Li M, Gao F, Qasim AN, Devaney JM, Burnett MS, Waterworth DM, Mooser V, Grant SF, Epstein SE, Reilly MP, Hakonarson H, Rader DJ. Pathway-Wide Association Study Implicates Multiple Sterol Transport and Metabolism Genes in HDL Cholesterol Regulation. Front Genet. 2011;2:41.
6. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, Rothblat GH, Lund-Katz S, Phillips MC. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem. 2007;282:25123-25130.
7. Blanco-Vaca F, Escolá-Gil JC, Martín-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res. 2001;42:1727-1739.
8. Klucken J, Büchler C, Orsó E, Kaminski WE, Porsch-Ozcürümez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA. 2000;97:817-822.
9. Barrans A, Collet X, Barbaras R, Jaspard B, Manent J, Vieu C, Chap H, Perret B. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem. 1994;269:11572- 11577.
10. Francone OL, Royer L, Haghpassand M. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res. 1996;37:1268-1277.
11. Ma YQ, Thomas GN, Ng MC, Critchley JA, Cockram CS, Chan JC, Tomlinson B. Association of two apolipoprotein A-I gene MspI polymorphisms with high density lipoprotein (HDL)-cholesterol levels and indices of obesity in selected healthy Chinese subjects and in patients with early-onset type 2 diabetes. Clin Endocrinol (Oxf). 2003;59:442-449.
12. Yamakawa-Kobayashi K, Yanagi H, Yu Y, Endo K, Arinami T, Hamaguchi H. Associations between serum high-density lipoprotein cholesterol or apolipoprotein AI levels and common genetic variants of the ABCA1 gene in Japanese school-aged children. Metab Clin Exp. 2004;53:182-186.
13. Tsai MY, Li N, Sharrett AR, Shea S, Jacobs DR Jr, Tracy R, Arnett D, Arends V, Post W. Associations of genetic variants in ATP-binding cassette A1 and cholesteryl ester transfer protein and differences in lipoprotein subclasses in the multi-ethnic study of atherosclerosis. Clin Chem. 2009;55:481-488.
14. Xiao J, Zhang F, Wiltshire S, Hung J, Jennens M, Beilby JP, Thompson PL, McQuillan BM, McCaskie PA, Carter KW, Palmer LJ, Powell BL. The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population. Atherosclerosis. 2008;199:333-339.
15. Olivier M, Tanck MW, Out R, et al. Human ATP-binding cassette G1 controls macrophage lipoprotein lipase bioavailability and promotes foam cell formation. Arterioscler Thromb Vasc Biol. 2012;32:2223-2231.
16. Kuivenhoven JA, de Knijff P, Boer JM, Smalheer HA, Botma GJ, Seidell JC, Kastelein JJ, Pritchard PH. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol. 1997;17:560-568.
17. Frisdal E, Klerkx AH, Le Goff W, Tanck MW, Lagarde JP, Jukema JW, Kastelein JJ, Chapman MJ, Guerin M. Functional interaction between-629C/A,-971G/ A and-1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Mol Genet. 2005;14:2607-2618.
18. Couture P, Otvos JD, Cupples LA, Lahoz C, Wilson PW, Schaefer EJ, Ordovas JM. Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2000;20:815-822.
19. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580.
20. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
21. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365-375.
22. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
23. Chan DC, Hoang A, Barrett PH, Wong AT, Nestel PJ, Sviridov D, Watts GF. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux. J Clin Endocrinol Metab. 2012;97:E1658-E1666.
24. Hoang A, Drew BG, Low H, Remaley AT, Nestel P, Kingwell BA, Sviridov D. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J. 2012;33:657-665.
25. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Hamsten A, Kathiresan S, Mälarstig A, Ordovas JM, Ripatti S, Parker AN, Miletich JP, Ridker PM. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009;5:e1000730.
26. Gardner CD, Tribble DL, Young DR, Ahn D, Fortmann SP. Population frequency distributions of HDL, HDL(2), and HDL(3) cholesterol and apolipoproteins A-I and B in healthy men and women and associations with age, gender, hormonal status, and sex hormone use: the Stanford Five City Project. Prev Med. 2000;31:335-345.
27. Catalano G, Duchene E, Julia Z, Le Goff W, Bruckert E, Chapman MJ, Guerin M. Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects. J Lipid Res. 2008;49:635-643.
28. Benton JL, Ding J, Tsai MY, Shea S, Rotter JI, Burke GL, Post W. Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;193:352-360.
29. Carmena-Ramon RF, Ordovas JM, Ascaso JF, Real J, Priego MA, Carmena R. Influence of genetic variation at the apo A-I gene locus on lipid levels and response to diet in familial hypercholesterolemia. Atherosclerosis. 1998;139:107-113.
30. Ma XY, Liu JP, Song ZY. Associations of the ATP-binding cassette transporter A1 R219K polymorphism with HDL-C level and coronary artery disease risk: a meta-analysis. Atherosclerosis. 2011;215:428-434.
31. Morcillo S, Cardona F, Rojo-Martínez G, Almaraz MC, Esteva I, Ruiz-De-Adana MS, Olveira G, García-Fuentes E, Gómez-Zumaquero JM, Soriguer F. Effect of the combination of the variants-75G/A APOA1 and Trp64Arg ADRB3 on the risk of type 2 diabetes (DM2). Clin Endocrinol (Oxf). 2008;68:102-107.
32. Ruaño G, Seip RL, Windemuth A, et al. Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training. Atherosclerosis. 2006;185:65-69.
33. Tsai MY, Ordovas JM, Li N, Straka RJ, Hanson NQ, Arends VL, Arnett D. Effect of fenofibrate therapy and ABCA1 polymorphisms on highdensity lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Mol Genet Metab. 2010;100:118-122.
34. Castro G, Nihoul LP, Dengremont C, de Geitère C, Delfly B, Tailleux A, Fievet C, Duverger N, Denèfle P, Fruchart JC, Rubin EM. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 1997;36:2243-2249.
35. Chiesa G, Parolini C, Canavesi M, Colombo N, Sirtori CR, Fumagalli R, Franceschini G, Bernini F. Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. Arterioscler Thromb Vasc Biol. 1998;18:1417-1423.
36. Isaacs A, Sayed-Tabatabaei FA, Njajou OT, Witteman JC, van Duijn CM. The-514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab. 2004;89:3858-3863.
37. Borggreve SE, de Vries R, Dallinga-Thie GM, Wolffenbuttel BH, Groen AK, van Tol A, Dullaart RP. The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the-629C->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin: cholesterol acyltransferase activity. Biochim Biophys Acta. 2008;1781:10-15.
38. Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH, Kuivenhoven JA. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked-629C->A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet. 2003;12:111-123.
39. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-713.
40. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-169.
41. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RP; PREVEND Study Group. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab. 2006;91:3382-3388.
42. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Steffensen R, Tybjaerg-Hansen A. Genetic variation in ABCA1 predicts ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol. 2008;28:180-186.
43. van Acker BA, Botma GJ, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJ, Boer JM, Seidell JC, Jukema JW, Kastelein JJ, Jansen H, Verhoeven AJ; REGRESS Study Group. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis. 2008;200:161-167.
44. Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, Burbano RR, de Arruda Cardoso Smith M. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med. 2009;9:319-325.
45. Isaacs A, Aulchenko YS, Hofman A, Sijbrands EJ, Sayed-Tabatabaei FA, Klungel OH, Maitland-van der Zee AH, Stricker BH, Oostra BA, Witteman JC, van Duijn CM. Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels. J Clin Endocrinol Metab. 2007;92:2680-2687.
46. Takata M, Inazu A, Katsuda S, Miwa K, Kawashiri MA, Nohara A, Higashikata T, Kobayashi J, Mabuchi H, Yamagishi M. CETP (cholesteryl ester transfer protein) promoter-1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia. Clin Sci. 2006;111:325-331.
47. Joy TR. Novel HDL-based therapeutic agents. Pharmacol Ther. 2012;135:18-30.